Adinazolam

Revision as of 18:54, 27 September 2011 by WikiBot (talk | contribs) (Protected "Adinazolam": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Adinazolam
File:Adinazolam.svg
File:Adinazolam3d.png
Clinical data
Pregnancy
category
  • ?
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • Schedule IV(US)
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life< 3 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H18ClN5
Molar mass351.8

Adinazolam (Deracyn®) is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant[1] properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.[2]

Pharmacology

Adinazolam produces inhibitory effects by binding to GABA receptors. This increases the effects of GABA.

Metabolism

Adinazolam was reported to have active metabolites in the August 1984 issue of The Journal of Pharmacy and Pharmacology.[3] The main metabolite is N-desmethyladinazolam.[4] The other two metabolites are alpha-hydroxyalprazolam and estazolam.[5] In the August 1986 issue of that same journal, Sethy, Francis and Day reported that proadifen inhibited the formation of N-desmethyladinazolam.[6]

Indications

Adinazolam is indicated as a treatment for anxiety and status epilepticus.

References

  1. ↑ Lahti, Robert A. (1983). "Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine". Neuropharmacology. 22 (11): 1277–82. PMID 6320036. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  2. ↑ "Discovers Award 2004" (PDF). Special Publications. Pharmaceutical Research and Manufactureres of America. 2004. p. 39. Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Unknown parameter |accessmonthday= ignored (help); Unknown parameter |month= ignored (help)
  3. ↑ Sethy, Vimala H. (1984). "Determination of biological activity of adinazolam and its metabolites". Journal of Pharmacy and Pharmacology. 36 (8): 546–8. PMID 6148400. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  4. ↑ Peng, G. W. (1984). "Assay of adinazolam in plasma by liquid chromatography". Journal of Pharmaceutical Sciences. 73 (8): 1173–5. PMID 6491930. Unknown parameter |month= ignored (help)
  5. ↑ Fraser, A. D. (1993). "Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC". Journal of Analytical Toxicology. 17 (7): 427–31. PMID 8309217. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  6. ↑ Sethy, Vimala H. (1986). "The effect of proadifen on the metabolism of adinazolam". Journal of Pharmacy and Pharmacology. 38 (8): 631–2. PMID 2876087. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)

Template:Benzodiazepines

Template:Psychoactive-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Adinazolam&oldid=604667"